Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659501 · ClinicalTrials.gov registry record · NA
Liposomal Bupivacaine in Implant Based Breast Reconstruction
A NA study, sponsored by Loma Linda University.
- Terminated
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT02659501 is a NA study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 24 participants.
The verdict
NCT02659501, a NA study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Objectives: 1. To evaluate the effect of liposomal bupivacaine on postoperative pain levels. 2. To evaluate the effect of liposomal bupivacaine on postoperative opioid consumption and opioid related adverse events. 3. To evaluate the effect of liposomal bupivacaine on length of hospital stay. 4. To evaluate the effect of liposomal bupivacaine on patient satisfaction with postoperative pain control. 5. To evaluate the effect of liposomal bupivacaine on overall patient satisfaction.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Hydrocodone/acetaminophen
- DRUG Diazepam
- DRUG Morphine sulfate
- DRUG Bupivacaine with epinephrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659501
The ClinicalTrials.gov registry entry for NCT02659501 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Liposomal bupivacaine is the first listed.
NCT02659501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659501 about?
NCT02659501 is a clinical study titled "Liposomal Bupivacaine in Implant Based Breast Reconstruction". Objectives: 1. To evaluate the effect of liposomal bupivacaine on postoperative pain levels. 2. To evaluate the effect of liposomal bupivacaine on postoperative opioid consumption and opioid related adverse events. 3. To evaluate the effect of liposomal bupivacaine on length of hospital stay. 4. To...
What is the current status of trial NCT02659501?
This trial is currently terminated. It is a NA study. The enrollment target is 24 participants. The study started on 2015-07. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02659501?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Hydrocodone/acetaminophen (DRUG), Diazepam (DRUG), Morphine sulfate (DRUG), Bupivacaine with epinephrine (DRUG).
Who is sponsoring clinical trial NCT02659501?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.